[The characteristics of gastrozepin pharmacokinetics in patients with gastric and duodenal peptic ulcers].
The individual variations in the blood concentrations of gastrocepine, the period of its half-life and clearance in patients with peptic ulcers of the stomach and the duodenal bulb were determined. The patients having combined forms of peptic ulcer with chronic liver diseases exhibited most often an increase of gastrocepine half-life. A new metabolite of gastrocepine was identified by using the chromato-mass-spectral analysis. The specific antibodies to gastrocepine determining the decrease of its concentration in blood and the development of the drug resistance were found.
Loginov
A S
AS
Sil'vestrova
S Iu
SIu
Bendikov
E A
EA
Giliadova
L A
LA
D000906:Antibodies / Q000032:analysis; D000918:Antibody Specificity; D002855:Chromatography, Thin Layer; D004351:Drug Resistance; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000378:metabolism*; D008401:Gas Chromatography-Mass Spectrometry; D006207:Half-Life; D006521:Hepatitis, Chronic / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D010890:Pirenzepine / Q000032:analysis / Q000276:immunology / Q000493:pharmacokinetics*; D013276:Stomach Ulcer / Q000188:drug therapy / Q000378:metabolism*; D013997:Time Factors
D000906:Antibodies; D010890:Pirenzepine
Osobennosti farmakokinetiki gastrotsepina u bol'nykh iazvennoĭ bolezn'iu zheludka i dvenadtsatiperstnoĭ kishki.